Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Yamagishi, Naoko ^a   Teshima Kondo, Shigetada ^a   Masuda, Kiyoshi ^a   Nishida, Kensei ^a   Kuwano, Yuki ^a   Dang, Duyen T ^b   Dang, Long H ^c   Nikawa, Takeshi ^a   Rokutan, Kazuhito ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR CELL DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESISTANCE; GENE; GENE DISRUPTION; GENE PRODUCT; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; NICK END LABELING; PHENOTYPE; SPHEROID CELL; VEGF GENE;

ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; APOPTOSIS; ENZYME INHIBITORS; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; PHENOTYPE; PREGNANCY PROTEINS; SPHEROIDS, CELLULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84877039223     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-229     Document Type: Article

References (29)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342. 10.1056/NEJMoa032691, 15175435.
2. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8(8):592-603. 10.1038/nrc2442, 2874834, 18650835.
3. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008, 14(20):6371-6375. 10.1158/1078-0432.CCR-07-5287, 18927275.
4. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Update 2008, 11(6):219-230.
5. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009, 15(16):5020-5025. 10.1158/1078-0432.CCR-09-0095, 2743513, 19671869.
6. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing of fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009, 15(3):167-170. 10.1016/j.ccr.2009.02.007, 19249675.
7. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, Ellis LM. Expression and function of vascular endothelial growth factor receptor 1 on human colorectal cancer cells. Oncogene 2005, 24(16):2647-2653. 10.1038/sj.onc.1208246, 15735759.
8. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, Mercurio AM. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001, 61(15):5736-5740.
9. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, Saab KR, Osherov V, Widlund HR, Gasser M, Waaga-Gasser AM, Kupper TS, Murphy GF, Frank MH. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2011, 71(4):1474-1485. 10.1158/0008-5472.CAN-10-1660, 3083845, 21212411.
10. Tian X, Song S, Wu J, Meng L, Dong Z, Shou C. Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun 2001, 286(2):505-512.
11. Fan F, Samuel S, Gaur P, Lu J, Dallas NA, Xia L, Bose D, Ramachandran V, Ellis LM. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumor cell migration. Br J Cancer 2011, 104(8):1270-1277. 10.1038/bjc.2011.81, 3078594, 21407219.
12. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231. 10.1016/j.ccr.2009.01.027, 2874829, 19249680.
13. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15(3):232-239. 10.1016/j.ccr.2009.01.021, 19249681.
14. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379(6560):88-91. 10.1038/379088a0, 8538748.
15. Masuda K, Teshima-Kondo S, Mukaijo M, Yamagishi N, Nishikawa Y, Nishida K, Kawai T, Rokutan K. A novel tumor-promoting function residing in the 5′ non-coding region of vascular endothelial growth factor mRNA. PLoS Med 2008, 5(5):e94. 10.1371/journal.pmed.0050094, 2386836, 18494554.
16. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007, 4(6):e186. 10.1371/journal.pmed.0040186, 1885450, 17550303.
17. Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, Kantsevoy SV, Dang LH. Hypoxia-inducible factor-1 alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 2006, 66(3):1684-1693. 10.1158/0008-5472.CAN-05-2887, 16452228.
18. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10):721-732. 10.1038/nrc1187, 13130303.
19. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148(3):399-408. 10.1016/j.cell.2012.01.021, 3437543, 22304911.
20. Takeda T, Okuyama H, Nishizawa Y, Tomita S, Inoue M. Hypoxia inducible factor-1α is necessary for invasive phenotype in vegf-deleted islet cell tumors. Sci Rep 2012, 2:494. 3389366, 22768384.
21. Kim YJ, Lee HJ, Kim TM, Eisinger-Mathason TS, Zhang AY, Schmidt B, Karl DL, Nakazawa MS, Park PJ, Simon MC, Yoon SS. Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α. Int J Cancer 2013, 132(1):29-41. 10.1002/ijc.27666, 22684860.
22. Masuda K, Abdelmohsen K, Gorospe M. RNA-binding proteins implicated in the hypoxic response. J Cell Mol Med 2009, 13(9A):2759-2769. 10.1111/j.1582-4934.2009.00842.x, 2832090, 19583805.
23. Yoshii Y, Waki A, Yoshida K, Kakezuka A, Kobayashi M, Namiki H, Kuroda Y, Kiyono Y, Yoshii H, Furukawa T, Asai T, Okazawa H, Gelovani JG, Fujibayashi Y. The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation. Biomaterials 2011, 32(26):6052-6058.
24. Karlsson H, Fryknäs M, Larsson R, Nygren P. Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp Cell Res 2012, 318(13):1577-1585. 10.1016/j.yexcr.2012.03.026, 22487097.
25. Samuel S, Fan F, Dang LH, Xia L, Gaur P, Ellis LM. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 2011, 30(10):1205-1212. 10.1038/onc.2010.496, 3224802, 21057529.
26. Calvani M, Trisciuoglio D, Bergamaschi C, Shoemaker RH, Melillo G. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res 2008, 68(1):285-291. 10.1158/0008-5472.CAN-07-5564, 18172321.
27. Lu KV, Chang JP, Parachoniak MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22(1):21-35. 10.1016/j.ccr.2012.05.037, 22789536.
28. Vakkalanka BK, Rini BI. Targeted therapy in renal cell carcinoma. Curr Opin Urol 2008, 18(5):481-487. 10.1097/MOU.0b013e32830a70cf, 18670271.
29. Escudier B, Cosaert J, Pisa P. Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Rev Anticancer Ther 2008, 8(10):1545-1557. 10.1586/14737140.8.10.1545, 18925847.